Validea Detailed Fundamental Analysis

Validea's Multi-Factor Investor model, leveraging Pim van Vliet's low-volatility strategy, assigned AMGEN (AMGN) an 87% rating, signifying "some interest" based on its underlying fundamentals and valuation. This model, which targets low-volatility stocks with strong momentum and high net payout yields, found AMGN passed market cap and standard deviation criteria. However, AMGN was neutral on twelve-minus-one momentum and net payout yield, and failed the final rank, despite the strategy's premise that low-volatility stocks can outperform with less risk.

Analysis

Amgen Inc. (AMGN) received a moderately positive rating of 87% from Validea's Multi-Factor Investor model, which is based on Pim van Vliet's strategy of targeting low-volatility stocks with strong momentum and high net payout yields. This score, which typically indicates 'some interest,' reflects the company's successful adherence to the model's low-risk criteria, passing tests for market capitalization and standard deviation. However, this initial positive assessment is contradicted by a 'FAIL' on the model's final composite rank. The weakness stems from AMGN's 'NEUTRAL' performance on two key return-driving factors for this specific strategy: 'twelve minus one momentum' and 'net payout yield'. Therefore, while the large-cap biotech firm exhibits the desired low-volatility characteristics, it does not currently meet the full criteria for momentum and shareholder returns required to be considered a strong candidate under this particular factor-based investment model.

Key Decisions for Investors

• Investors following a strict low-risk, high-momentum factor strategy should be cautious, as AMGN failed the model's final rank due to neutral scores on momentum and net payout yield.
• For investors prioritizing capital preservation, AMGN's successful low-volatility screening is a positive signal, but further due diligence is required to understand the weakness in its momentum and shareholder yield.
• The conflicting signals—a high initial score of 87% but a final 'FAIL'—suggests that while AMGN has desirable conservative traits, it may not be an ideal candidate for outperformance according to this specific multi-factor model.